A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer

Programmed cell death-1 (PD-1) immune checkpoint inhibitor antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1 (PD-L1). However, there are currently no prospective studies evaluating PD-L1 expression for small biop...

Full description

Saved in:

Bibliographic Details
Published in:	BMC cancer Vol. 19; no. 1; p. 546
Main Authors:	Tsunoda, Akihito, Morikawa, Kei, Inoue, Takeo, Miyazawa, Teruomi, Hoshikawa, Masahiro, Takagi, Masayuki, Mineshita, Masamichi
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 07-06-2019 BioMed Central BMC
Subjects:	Adenocarcinoma Antibodies Apoptosis Biochemistry Bronchoscopy Carcinoma CAT scans Cell death Clinical trials Diagnosis Diagnostic imaging Ethics Genetic aspects Immunohistochemistry Lung biopsy Lung cancer Medical ethics Non-small cell lung cancer Pathology Respiratory system agents Small cell lung cancer Squamous cell carcinoma Tomography Tumors Ultrasound imaging Bronchoscopy Immunohistochemistry Pathology Lung cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!